These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8522464)

  • 1. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital.
    Fass RJ; Barnishan J; Ayers LW
    J Antimicrob Chemother; 1995 Aug; 36(2):343-53. PubMed ID: 8522464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA; Nathan C; Delzell D; Kabins SA
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem and meropenem activity against mecA-positive homogeneously and heterogeneously oxacillin-resistant and mecA-negative oxacillin-borderline-susceptible staphylococci.
    Knapp CC; Ludwig MD; Washington JA
    Diagn Microbiol Infect Dis; 1997 Jun; 28(2):81-6. PubMed ID: 9239499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.
    Friedland IR; Isaacs R; Mixson LA; Motyl M; Woods GL
    Diagn Microbiol Infect Dis; 2002 May; 43(1):61-4. PubMed ID: 12052630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
    Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
    Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.
    Reynolds R; Potz N; Colman M; Williams A; Livermore D; MacGowan A;
    J Antimicrob Chemother; 2004 Jun; 53(6):1018-32. PubMed ID: 15128723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.
    Cambau E; Perani E; Dib C; Petinon C; Trias J; Jarlier V
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2248-52. PubMed ID: 8619577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RO23-6240, a new orally absorbed quinolone: in vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem.
    Aldridge KE; Schiro DD; Sanders CV
    Diagn Microbiol Infect Dis; 1987 May; 7(1):9-19. PubMed ID: 3121244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G; Zarakolu P; Hasçelik G; Akova M
    Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories.
    Steward CD; Wallace D; Hubert SK; Lawton R; Fridkin SK; Gaynes RP; McGowan JE; Tenover FC
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):59-67. PubMed ID: 11025185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
    Piddock LJ; Johnson MM; Webber MA
    J Antimicrob Chemother; 2003 Sep; 52(3):500-2. PubMed ID: 12917244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acinetobacter baumannii at a tertiary-care teaching hospital in Jerusalem, Israel.
    Simhon A; Rahav G; Shazberg G; Block C; Bercovier H; Shapiro M
    J Clin Microbiol; 2001 Jan; 39(1):389-91. PubMed ID: 11136809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains.
    Aldridge KE; Jones RN; Barry AL; Gelfand MS
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):517-21. PubMed ID: 1330418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin.
    Rådberg G; Nilsson LE; Svensson S
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2142-7. PubMed ID: 2127345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
    Sousa D; Castelo-Corral L; Gutiérrez-Urbón JM; Molina F; López-Calviño B; Bou G; Llinares P
    J Antimicrob Chemother; 2013 Aug; 68(8):1917-25. PubMed ID: 23557925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.
    Ogle JW; Reller LB; Vasil ML
    J Infect Dis; 1988 Apr; 157(4):743-8. PubMed ID: 3126247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.